MBI Logo
MBI Logo

Current Topics Workshop: Chemogenomics (May 8-10, 2007)

(partially supported by the College of Medicine)

Organizers: Paul Blower, Joe Verducci, John Weinstein, and Stan Young

Advances in high throughput chemogenomic profiling such as yeast deletion libraries and whole genome shRNA-based loss-of-function arrays for human and mouse genes promise to accelerate the discovery of potential drug targets and increase understanding of complex interactions between components of a biological system. Chemogenomics can be defined as the use of genomics to measure the system-wide effect of a compound on an intact biological system, either single cells or whole organisms. It combines high-throughput genomics or proteomic profiling with chemoinformatic and statistical analysis to study the response of a biological system to chemical compounds. Cellular response is measured by phenotypic readouts in a high-throughput assay. Chemogenomics also investigates the consequences of differential gene/protein expression on cellular response to compound treatment. For example, expression levels of membrane transporters can have a dramatic effect on compound potency.

Chemogenomics as a discipline has been molded by access to the suite of datasets related to a panel of 60 cancer cell lines from the National Cancer Institute (NCI-60). This is an unparalleled public resource for elucidating molecular targets and mechanisms of chemosensitivity/resistance, with cytotoxic potencies for >50,000 compounds, as well as mRNA profiles and proteomes. In addition, the NCI-60 repertory will soon include expression patterns of microRNAs which can resolve discordant relationships between mRNA and protein expression profiles. The response of cancers to drug treatment is a biological process that cannot be understood by studying individual genes or proteins in isolation. The NCI-60 datasets provide significant opportunities for large-scale datamining and applications of statistical modeling of drug potencies based on mRNA/protein/miRNA expression, alone or in combination with aspects of molecular structure of the drug candidates.

In this workshop, we will survey advances in experimental techniques for high throughput profiling, statistical design and assessment for association, and chemoinformatic techniques for large-scale datamining of compound-gene associations. Chemogenomics draws on many scientific disciplines, and this workshop is intended to foster cross-discipline understanding and lead to long-term collaborations among participants. Conference presenters and discussion leaders will include experimental molecular biologists as well as scientists specializing in statistics, chemoinformatics and drug discovery applications.

Schedule

Tuesday, May 8
8:00-8:45am Continental breakfast
8:45-9:00am Welcome and introduction by Avner Friedman
9:00-9:45am John Weinstein
9:45-10:00am Coffee break
10:00-10:45am Clara Bloomfield: Current use of molecular abnormalities in acute leukemia for selecting treatment
10:45-11:00am Coffee break
11:00-11:45am Georges Natsoulis
11:45-2:00pm Lunch
2:00-2:45pm John Overington: Construction of a large-scale chemogenomics data from published data
2:45-3:00pm Coffee break
3:00-3:45pm Peter Willett: Measurement of structural similarity for chemical database searching
3:45-4:00pm Coffee break
4:00-4:45pm Wolfgang Sadee: Bridging computational approaches with laboratory experiments: A question of scale
5:00-7:00pm Reception in MW 724
Wednesday, May 9
8:30-9:00am Continental breakfast
9:00-9:45am Stan Young: Non-Negative Matrix Factorization for Statistical Analysis
9:45-10:00am Coffee break
10:00-10:45am David Covell: In Silico Strategies for Mining the NCI's Screening, Hollow Fiber and Xenograft Data
10:45-11:00am Coffee break
11:00-11:45am Justin Lamb: The Connectivity Map: Using gene-expression profiling to identify new therapeutics and potential adverse drug effects
11:45-2:00pm Lunch
2:00-2:45pm Dimitris Agrafiotis: New algorithms for mining large data sets
2:45-3:00pm Coffee break
3:00-3:45pm Eric Kaldjian: Evolving a practical approach to multi-platform microarray analysis for clinical applications
3:45-4:00pm Coffee break
4:00-5:00pm Panel discussion
6:00-6:30pm Reception at the Holiday Inn on the Lane (cash bar)
6:30pm Dinner at the Holiday Inn on the Lane
Thursday, May 10
8:30-9:00 Continental breakfast
9:00-9:45am Gerhard Mueller: The Privileged Structure Concept: from targets to compounds to targets by means of chemogenomics
9:45-10:00am Coffee break
10:00-10:45am Takao Yamori: Identification of candidates for new drug, target and biomarker by mining data sets from a panel of human cancer cell lines: JFCR39
10:45-11:00am Coffee break
11:00-11:45am Paul Blower: Informatics and experimental studies of chemoresistance